The RSV Expert Meeting brought together over 100 in-person attendees and more than 300 online participants to explore the evolving landscape of respiratory syncytial virus prevention and immunisation in Australia.
The meeting featured leading experts discussing RSV infection trends among infants and older adults, early outcomes from the monoclonal antibody program, and insights from the maternal vaccination rollout. Strategies to improve vaccination uptake among adults aged 60 and over were also a key focus. A panel discussion addressed the challenges and opportunities in maternal and infant RSV immunisation, as well as the broader impact of age-targeted strategies.
The meeting provided an important platform for healthcare professionals, policymakers and researchers to share evidence, experiences, and recommendations aimed at strengthening RSV vaccination efforts. Outcomes from the discussion will be documented and shared with government stakeholders to be considered for future immunisation strategies and vaccination implementation.
We extend our sincere thanks to Professor Paul Griffin for chairing the meeting, Dr Sarah Chu for moderating the panel discussion and to all speakers for their valuable contributions. Our thanks to our Platinum sponsor Sanofi and our Gold sponsors, GSK, MSD, Moderna and Pfizer for their generous support.
